flowchart TD
A["MAPT/Tau Protein Microtubule Stabilizer"]
B["CDK5/GSK3B Activation Kinase Dysregulation"]
C["Tau Hyperphosphorylation Ser396/Thr231/Ser202"]
D["Tau Detachment Microtubule Destabilized"]
E["Tau Oligomers Paired Helical Filaments"]
F["Neurofibrillary Tangles Intraneuronal Inclusions"]
G["Axonal Transport Failure Synaptic Dysfunction"]
H["Neurodegeneration Tauopathy Spread"]
A --> B
B --> C
C --> D
D --> E
E --> F
D --> G
G --> H
F --> H
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Median TPM across 13 brain regions for MAPT from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations7 with PMID3 high-strengthValidation: 0%5 supporting / 2 opposing
✓For(5)
3
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
1
3
MECH 3CLIN 1GENE 3EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Glymphatic impairment directly reduces tau clearan…
Glymphatic impairment directly reduces tau clearance in AD mouse models, with AQP4 polarization loss as the pr…HIGH▼
Glymphatic impairment directly reduces tau clearance in AD mouse models, with AQP4 polarization loss as the primary mechanism — foundational evidence for the hypothesis.
Glymphatic and meningeal lymphatic dysfunction are core features of AD pathophysiology, reducing both amyloid-…HIGH▼
Glymphatic and meningeal lymphatic dysfunction are core features of AD pathophysiology, reducing both amyloid-beta and tau clearance and representing a disease-modifying therapeutic target.
Removal of astrocytic PERK restores glymphatic function and reduces pathological tau aggregate clearance failu…MODERATE▼
Removal of astrocytic PERK restores glymphatic function and reduces pathological tau aggregate clearance failure, linking ER stress to glymphatic tau accumulation.
Glymphatic pathway impairment promotes tau pathology accumulation after TBI — establishes the causal link betw…HIGH▼
Glymphatic pathway impairment promotes tau pathology accumulation after TBI — establishes the causal link between glymphatic failure and tau spreading.
Sleep-dependent glymphatic clearance of tau and amyloid is impaired in AD, with proteomics data identifying sp…MODERATE▼
Sleep-dependent glymphatic clearance of tau and amyloid is impaired in AD, with proteomics data identifying specific transport proteins dysregulated in glymphatic failure.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF we enroll 120 early-stage Alzheimer's disease subjects (CDR 0.5, amyloid positive by PET) and randomize to 6 months of sleep optimization intervention (auto-CPAP for AHI>15 + sleep hygiene counseling + trazodone 50mg PRN for insomnia) versus standard care, THEN the intervention group will exhibit a ≥25% reduction in CSF p-tau181 concentration (Lumipulse) compared to baseline and a ≥20% lower mean CSF p-tau181 than the control group at 6 months.
pendingconf: 0.65
Expected outcome: ≥25% decrease in CSF p-tau181 from baseline in intervention arm; ≥20% lower mean CSF p-tau181 in intervention vs control arm at 6 months
Falsified by: CSF p-tau181 in the intervention arm remains unchanged or increases; the difference between arms is <20% at 6 months; or no correlation exists between sleep efficiency improvement and p-tau181 reduction
Method: Multi-site randomized controlled trial (R01-AG-like design), early AD cohort, CSF sampling via lumbar catheter at baseline and 6 months, p-tau181 quantified by Lumipulse G1200, polysomnography-measured sleep efficiency as covariate
IF we recruit 180 amnestic MCI and early AD subjects (CDR 0.5–1.0), stratify them into APOE4 carriers (n=60), APOE4 non-carriers with high sleep fragmentation (ESS >10 or PSG AHI 15–30, n=60), and APOE4 non-carriers with normal sleep (n=60), and perform 7T MRI measuring perivascular space (PVS) volume in centrum semiovale plus CSF p-tau181 and total tau, THEN APOE4 carriers will demonstrate ≥50% larger total PVS volume (mm³) and ≥35% higher CSF p-tau181 compared to normal-sleep non-carriers, with APOE4 status explaining ≥15% of variance in PVS volume after adjusting for age, sex, and vascular risk.
pendingconf: 0.55
Expected outcome: ≥50% larger PVS volume in APOE4 carriers vs normal-sleep non-carriers; ≥35% higher CSF p-tau181 in APOE4 carriers; APOE4 explains ≥15% of PVS variance
Falsified by: No significant difference in PVS volume between APOE4 carriers and normal-sleep non-carriers (p>0.05); CSF p-tau181 does not differ across groups; APOE4 explains <5% of PVS volume variance
Method: Cross-sectional stratified cohort study, 7T MRI with semi-automated PVS segmentation, polysomnography, CSF collection via lumbar puncture within 30 days of imaging, APOE genotyping, quantified by Simoa p-tau181 and total tau